At least two Neuralink employees have posted to LinkedIn in recent days saying they’ve been laid off from Elon Musk’s brain-computer interface startup, which has received backlash for animal testing.

A former staffer working on preclinical study design and an ex-lab director working on assessing the safety of Neuralink’s implanted devices (prior to human testing) announced recently they’d been laid off, specifically using that terminology. Both had worked at the startup for at least two years.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Another artificial intelligence startup has entered the drug discovery field, this time on a mission to fuel new RNA small molecules.

Atomic AI revealed a $35 million Series A Wednesday morning to boost its computational and wet lab work. The 14-employee startup will use the proceeds to continue building out its so-called PARSE platform, which is focused on predicting the 3D structure of RNA.

“There are a number of RNA transcripts of interest that we want to drug with small molecules, specifically, and a major issue across the field is that it is hard to get selective functional small molecule binders to those transcripts,” CEO and founder Raphael Townshend told Endpoints News in a preview. “And oftentimes, the mechanism of action is decreasing the amount of protein being expressed.”

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN